DBTX

Decibel Therapeutics, Inc. [DBTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

DBTX Stock Summary

Top 10 Correlated Stocks

DBTX


In the News

06:32 27 Sep 2023 DBTX

Decibel Therapeutics' CVR Appears Around Fair Value

Decibel Therapeutics is being acquired by Regeneron for a cash consideration of $4/share and a CVR linked to DB-OTO. DB-OTO is a gene therapy for hearing loss, with a phase 1/2 trial underway. The CVR broadly pays out with the early stages of the Phase III trial and subsequently the filing of a BLA application (or European equivalent).

12:35 27 Sep 2023 DBTX

Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals

Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline.

10:00 27 Sep 2023 DBTX

Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal

Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This deal has Regeneron Pharmaceuticals agreeing to acquire Decibel Therapeutics for $4 per share in cash.

09:43 27 Sep 2023 DBTX

Decibel Therapeutics shoots up 72% on Regeneron bid

Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be a knock-out bid for the tiny drug developer. The deal values Decibel Therapeutics, which is working on treatments aimed at enhancing and restoring hearing and balance, at $109 million.

07:55 27 Sep 2023 DBTX

Regeneron buying small cap Decibel Therapeutics for $4 a share

Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its closing price of $2.79 a share in the previous session. Boston-based Decibel Therapeutics is a clinical-stage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance.

04:30 27 Sep 2023 DBTX

Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy

04:30 27 Sep 2023 DBTX

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Los Angeles, California May 16 – 20th, 2023.

07:00 27 Sep 2023 DBTX

Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.

07:00 27 Sep 2023 DBTX

Decibel Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September.

01:28 27 Sep 2023 DBTX

Top Penny Stocks Today? 3 You Might Want To Watch Before Next Week

Penny stocks to watch before the end of the week. The post Top Penny Stocks Today?

DBTX Financial details

Company Rating
Neutral
Market Cap
123.37M
Income
-63.39M
Revenue
0
Book val./share
2.13
Cash/share
3.13
Dividend
-
Dividend %
-
Employees
68
Optionable
No
Shortable
Yes
Earnings
07 Nov 2023
P/E
-1.94
Forward P/E
-
PEG
-2.89
P/S
-
P/B
2.3
P/C
1.57
P/FCF
-2.5
Quick Ratio
2.95
Current Ratio
3.03
Debt / Equity
0.24
LT Debt / Equity
0.17
-
-
EPS (TTM)
-2.54
EPS next Y
-
EPS next Q
-
EPS this Y
5.88%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
37.74%
-
-
-
-
SMA20
-
SMA50
66.67%
SMA100
66.67%
Inst Own
61.56%
Inst Trans
1%
ROA
-67%
ROE
-84%
ROC
-0.97%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
25.13M
Shs Float
13.34M
-
-
-
-
Target Price
-
52W Range
1.61-5.4
52W High
-1.8%
52W Low
+391%
RSI
54
Rel Volume
5.96
Avg Volume
211.63K
Volume
1.26M
Perf Week
-3.73%
Perf Month
-3.91%
Perf Quarter
52.96%
Perf Half Y
76.62%
-
-
-
-
Beta
-0.436328
-
-
Volatility
0.04%, 0.08%
Prev Close
0%
Price
4.91
Change
-0.2%

DBTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-4.98-5.61-1.63-2.38-2.52
Operating cash flow per share
-4.97-6.72-1.41-1.99-2.28
Free cash flow per share
-5.15-6.81-1.42-2.02-2.3
Cash per share
11.334.392.356.844.19
Book value per share
7.922.15-7.046.523.28
Tangible book value per share
7.922.15-7.046.523.28
Share holders equity per share
7.922.15-7.046.523.28
Interest debt per share
000.220.20.61
Market cap
130.85M132.63M416.94M101.06M51.17M
Enterprise value
119.53M114.03M389.39M64.82M30.61M
P/E ratio
-3.62-3.21-11.08-1.95-0.81
Price to sales ratio
00000
POCF ratio
-3.63-2.68-12.77-2.34-0.9
PFCF ratio
-3.5-2.65-12.66-2.3-0.89
P/B Ratio
2.288.37-2.560.710.63
PTB ratio
2.288.37-2.560.710.63
EV to sales
00000
Enterprise value over EBITDA
-3.29-2.69-9.84-1.33-0.49
EV to operating cash flow
-3.31-2.31-11.92-1.5-0.54
EV to free cash flow
-3.2-2.27-11.82-1.48-0.53
Earnings yield
-0.28-0.31-0.09-0.51-1.23
Free cash flow yield
-0.29-0.38-0.08-0.43-1.12
Debt to equity
00-0.030.030.17
Debt to assets
000.080.020.11
Net debt to EBITDA
0.310.440.70.740.33
Current ratio
7.63.552.987.994.81
Interest coverage
0000-53.66
Income quality
11.160.830.830.9
Dividend Yield
000.130.270
Payout ratio
00-1.46-0.530
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.040.010.010.020.01
Capex to revenue
00000
Capex to depreciation
-0.87-0.41-0.17-0.53-0.32
Stock based compensation to revenue
00000
Graham number
29.7916.4916.0518.713.64
ROIC
-0.69-2.690.24-0.36-0.58
Return on tangible assets
-0.39-0.96-0.56-0.28-0.51
Graham Net
6.40.72-7.565.272.52
Working capital
72.61M24.12M38.45M143.65M85.59M
Tangible asset value
57.45M15.85M-162.69M141.69M81.79M
Net current asset value
47.78M6.58M-172.15M121.4M66.45M
Invested capital
00-0.030.030.17
Average receivables
00618.5K6.32M5.7M
Average payables
01.04M1.57M3.07M2.54M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.63-2.60.23-0.37-0.77
Capex per share
-0.18-0.1-0.01-0.03-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-0.68-0.64-0.64-0.53-0.73
Operating cash flow per share
-0.54-0.55-0.31-0.68-0.41
Free cash flow per share
-0.54-0.55-0.32-0.69-0.41
Cash per share
5.034.484.193.523.13
Book value per share
4.483.883.282.792.13
Tangible book value per share
4.483.883.282.792.13
Share holders equity per share
4.483.883.282.792.13
Interest debt per share
0.620.60.590.510.51
Market cap
105.08M86.37M51.17M75.47M96.32M
Enterprise value
64M64.41M30.61M50.8M69.36M
P/E ratio
-1.54-1.35-0.8-1.42-1.33
Price to sales ratio
00000
POCF ratio
-7.84-6.3-6.59-4.42-9.38
PFCF ratio
-7.77-6.28-6.43-4.36-9.39
P/B Ratio
0.940.890.631.081.81
PTB ratio
0.940.890.631.081.81
EV to sales
00000
Enterprise value over EBITDA
-3.82-4.03-1.9-3.69-3.71
EV to operating cash flow
-4.77-4.7-3.94-2.98-6.76
EV to free cash flow
-4.73-4.68-3.84-2.93-6.76
Earnings yield
-0.16-0.19-0.31-0.18-0.19
Free cash flow yield
-0.13-0.16-0.16-0.23-0.11
Debt to equity
0.140.150.170.190.24
Debt to assets
0.10.10.110.120.14
Net debt to EBITDA
2.451.371.281.791.44
Current ratio
6.185.44.814.143.03
Interest coverage
-180.03-43.71-24.9818.680
Income quality
0.790.860.491.280.57
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.0100.030.020
Capex to revenue
00000
Capex to depreciation
-0.33-0.13-0.53-0.780.04
Stock based compensation to revenue
00000
Graham number
8.37.486.865.795.9
ROIC
-0.12-0.13-0.15-0.15-0.24
Return on tangible assets
-0.11-0.11-0.13-0.12-0.19
Graham Net
3.472.962.522.031.49
Working capital
118.53M102.91M85.59M72.69M53.87M
Tangible asset value
111.86M96.81M81.79M69.84M53.31M
Net current asset value
94.99M80.83M66.45M55.26M39.37M
Invested capital
0.140.150.170.190.24
Average receivables
10M10M5M2.2M2.2M
Average payables
1.56M2.47M2.05M1.17M947.5K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.15-0.17-0.19-0.19-0.34
Capex per share
00-0.01-0.010

DBTX Frequently Asked Questions

What is Decibel Therapeutics, Inc. stock symbol ?

Decibel Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol DBTX

What is Decibel Therapeutics, Inc. stock quote today ?

Decibel Therapeutics, Inc. stock price is $4.91 today.

Is Decibel Therapeutics, Inc. stock public?

Yes, Decibel Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap